ACE2 and Hypertension: It was indicated that COVID-19 patients with hypertension who were treated with the angiotensin-converting enzyme inhibitors and the ACE2 blockers drugs were at lower risk of mortality when compared with those treated with other antihypertensive medication; the propensity score-matched and multivariable-adjusted HR was 0.30 (0.12–0.70) (18).